Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?

Since the beginning of SARS-CoV-2(severe acute respiratory syndrome-coronavirus-2) pandemic, a race to develop vaccine has been initiated, considering massive and rather significant economic healthcare hits that this virus caused. The pathophysiology occurring following COVID-19(coronavirus disease-2019) infection given hints regarding supportive symptomatic treatments establish for patients, as no specific anti-SARS-CoV-2 is available yet. Patient symptoms vary greatly range from mild severe fatal complications. Supportive include antipyretics, antiviral therapies, different combinations broad-spectrum antibiotics, hydroxychloroquine plasma transfusion. Unfortunately, cancer patients are at higher risk viral more likely serious complications due their immunocompromised state, fact they already administering multiple medications, well combined comorbidity compared general population. It may seem impossible find drug possesses both potent anticancer effects specifically against COVID-19 its existing malignancy, respectively. Thymoquinone (TQ) most pharmacologically active ingredient in Nigella sativa seeds (black seeds); it reported have anticancer, anti-inflammatory antioxidant various settings. In review, we will discuss TQ COVID-19, beneficial multiple-organ complications, use an adjuvant therapy therapy, finally, effects.